Just as EZH2 has been recognized as a marker of aggressive breast cancer and is associated with poor survival [27, 28], downregulation of EZH2 decreases the growth and metastasis of invasive breast carcinoma [29, 30], but EZH2 inhibitors alone have shown little benefit against breast cancer [31, 32]. Here, EZH2 is linked to breast carcinoma.